A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02396-0
Abstract: Purpose Compared with newer prandial anti-diabetes agents, repaglinide and acarbose are unique in being globally available in generic versions, being oral, and being the cheapest of all. The aim of this study was to compare… read more here.
Keywords: diabetes agents; prandial anti; group; acarbose repaglinide ... See more keywords
POTENTIAL UNREALIZED CARDIOVASCULAR BENEFIT OF NOVEL DIABETES AGENTS IN THE VETERANS HEALTH ADMINISTRATION SYSTEM: INSIGHT FROM THE CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32463-3
Abstract: Novel diabetes agents (glucagon-like-peptide-1 receptor agonists, GLP-1 RA and sodium-glucose cotransport-2 inhibitors, SGLT2i) reduced death and cardiovascular events in randomized trials, but uptake in clinical practice has lagged. We assessed the unrealized potential for reduction… read more here.
Keywords: potential unrealized; diabetes agents; unrealized cardiovascular; novel diabetes ... See more keywords